IWA
ITCI

Intercontinental Wealth Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Intercontinental Wealth Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-760
Closed -$10K – 443
2019
Q2 		$10K Hold
760
– – 0.01% 327
2019
Q1 		$9K Hold
760
– – ﹤0.01% 365
2018
Q4 		$9K Buy
+760
New +$12.3K 0.01% 370

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Intercontinental Wealth Advisors's ITCI Position: Q3 2019 in Review

Intercontinental Wealth Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2019, closing a stake of 760 shares — an estimated $10K sold.

Intercontinental Wealth Advisors first reported a position in ITCI in Q4 2018 and held it in 3 quarters. The position peaked at $10K in Q2 2019. 126 funds tracked by Wall St. Rank hold ITCI as of Q3 2019.

  • Intercontinental Wealth Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2019 after selling out during the quarter.
  • Intercontinental Wealth Advisors sold 760 Intra-Cellular Therapies Inc. shares in Q3 2019, an estimated $10K.
  • Intercontinental Wealth Advisors first reported a position in Intra-Cellular Therapies Inc. in Q4 2018 and held it in 3 quarters.
  • Intercontinental Wealth Advisors's Intra-Cellular Therapies Inc. position peaked at $10K in Q2 2019.
  • 126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2019.

Based on Intercontinental Wealth Advisors's 13F filing for Q3 2019, filed 9 Oct 2019.